Hemostemix Inc. (HMTXF)
USD 0.06
(-8.22%)
USD 0.06
(-8.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.33 Million CAD | 49.07% |
| 2022 | -4.58 Million CAD | 31.27% |
| 2021 | -2.76 Million CAD | 10.79% |
| 2020 | -7.47 Million CAD | -59.14% |
| 2019 | -4.69 Million CAD | 29.31% |
| 2018 | - CAD | -136.32% |
| 2017 | -2.77 Million CAD | 23.48% |
| 2016 | -2.57 Million CAD | 7.44% |
| 2015 | -3.94 Million CAD | 7.56% |
| 2014 | -4.29 Million CAD | -188.62% |
| 2013 | -1.48 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -364.06 Thousand CAD | -13.33% |
| 2024 Q1 | -325.71 Thousand CAD | 29.63% |
| 2023 Q4 | -413.58 Thousand CAD | -132.7% |
| 2023 FY | - CAD | 52.92% |
| 2023 Q1 | -1.13 Million CAD | -80.95% |
| 2023 Q2 | -278.64 Thousand CAD | 75.37% |
| 2023 Q3 | -177.73 Thousand CAD | 36.22% |
| 2022 Q4 | -625.18 Thousand CAD | 39.8% |
| 2022 Q2 | -1.58 Million CAD | -18.78% |
| 2022 Q1 | -1.33 Million CAD | 61.75% |
| 2022 FY | - CAD | 31.27% |
| 2022 Q3 | -1.03 Million CAD | 34.45% |
| 2021 Q4 | -3.48 Million CAD | -112.64% |
| 2021 Q2 | -1.4 Million CAD | -116.82% |
| 2021 Q3 | -1.63 Million CAD | -16.91% |
| 2021 FY | - CAD | 10.79% |
| 2021 Q1 | -646.96 Thousand CAD | 83.28% |
| 2020 Q4 | -3.86 Million CAD | -166.3% |
| 2020 FY | - CAD | -59.14% |
| 2020 Q3 | -1.45 Million CAD | 29.0% |
| 2020 Q2 | -2.04 Million CAD | -1623.03% |
| 2020 Q1 | -118.76 Thousand CAD | 78.53% |
| 2019 Q4 | -553.26 Thousand CAD | 57.25% |
| 2019 FY | - CAD | 29.31% |
| 2019 Q1 | -1.5 Million CAD | 23.93% |
| 2019 Q2 | -1.3 Million CAD | 13.43% |
| 2019 Q3 | -1.29 Million CAD | 0.88% |
| 2018 Q2 | -1.79 Million CAD | -37.31% |
| 2018 Q1 | -1.3 Million CAD | -310.75% |
| 2018 FY | - CAD | -136.32% |
| 2018 Q4 | -1.98 Million CAD | -27.72% |
| 2018 Q3 | -1.55 Million CAD | 13.64% |
| 2017 FY | - CAD | 23.48% |
| 2017 Q1 | -527.89 Thousand CAD | 37.74% |
| 2017 Q4 | 621.1 Thousand CAD | 121.66% |
| 2017 Q2 | -465.09 Thousand CAD | 11.9% |
| 2017 Q3 | -2.86 Million CAD | -516.48% |
| 2016 Q4 | -847.84 Thousand CAD | 46.1% |
| 2016 FY | - CAD | 7.44% |
| 2016 Q3 | -1.57 Million CAD | -154.6% |
| 2016 Q2 | -617.87 Thousand CAD | 5.44% |
| 2016 Q1 | -653.4 Thousand CAD | 44.25% |
| 2015 Q1 | -867.34 Thousand CAD | 60.29% |
| 2015 FY | - CAD | 7.56% |
| 2015 Q4 | -1.17 Million CAD | -19.71% |
| 2015 Q3 | -978.93 Thousand CAD | -3.09% |
| 2015 Q2 | -949.57 Thousand CAD | -9.48% |
| 2014 FY | - CAD | -188.62% |
| 2014 Q4 | -2.18 Million CAD | -164.29% |
| 2014 Q3 | -826.35 Thousand CAD | -2122.33% |
| 2014 Q2 | -37.18 Thousand CAD | -290.63% |
| 2014 Q1 | -9519.00 CAD | 40.39% |
| 2013 Q2 | -35.39 Thousand CAD | 31.73% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | -16.76 Thousand CAD | 52.62% |
| 2013 Q4 | -15.97 Thousand CAD | 4.76% |
| 2013 Q1 | -51.84 Thousand CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 38.921% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.715% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -875.671% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.362% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 11.765% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 86.567% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.481% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -51.904% |
| Marizyme, Inc. | -34.28 Million USD | 93.194% |
| Genus plc | 73.7 Million USD | 103.166% |
| Pharming Group N.V. | 9.87 Million USD | 123.624% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -56.871% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 34.217% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 73.4% |
| ContraFect Corporation | -64.99 Million USD | 96.41% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -66.451% |
| IMV Inc. | -35.52 Million USD | 93.432% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -0.409% |
| ONE Bio Corp. | 13.61 Million USD | 117.14% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 95.162% |
| Mesoblast Limited | -62.38 Million USD | 96.26% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -350.407% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 165.322% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.062% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -268.959% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2.137% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 60.645% |
| Biomind Labs Inc. | -1.03 Million USD | -125.54% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 19.327% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 67.418% |
| Skye Bioscience, Inc. | -13.54 Million USD | 82.777% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 34801.324% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 64.708% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -9233.268% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 48.449% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 39.93% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 85.297% |
| Accustem Sciences Inc. | -3.74 Million USD | 37.719% |
| EV Biologics, Inc. | -1.26 Million USD | -84.142% |
| Q BioMed Inc. | -617.62 Thousand USD | -277.787% |
| GB Sciences, Inc. | -1.41 Million USD | -64.331% |
| Alpha Cognition Inc. | -9.7 Million USD | 75.959% |
| CSL Limited | 4.78 Billion USD | 100.049% |
| Agentix Corp. | -1.37 Million USD | -70.097% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 94.113% |
| Enzolytics Inc. | -2.12 Million USD | -9.957% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 80.128% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 23.823% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 6.741% |
| argenx SE | -216.02 Million USD | 98.92% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.784% |
| HST Global, Inc. | -5303.00 USD | -43899.943% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 291.727% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -13.433% |
| Halberd Corporation | -74.27 Thousand USD | -3041.288% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 126.354% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 715.904% |
| Zenith Capital Corp. | -8.6 Million USD | 72.887% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -55.668% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 4.625% |
| AVAX Technologies, Inc. | -6.11 Million USD | 61.828% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1225.565% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -21.469% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13293.703% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -125.485% |
| Helix BioMedix, Inc. | -1.04 Million USD | -123.004% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -33.332% |
| Kadimastem Ltd | -2.62 Million USD | 11.091% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 69.11% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1188.499% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 665.95% |
| Cell Source, Inc. | -4.27 Million USD | 45.388% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -535.399% |
| Regen BioPharma, Inc. | 1.46 Million USD | 259.167% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -149.034% |
| Affymax, Inc. | -14.29 Million USD | 83.677% |
| Mobile Lads Corp. | -2.24 Million USD | -4.112% |
| Itoco Inc. | -1.86 Million USD | -24.843% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -514.645% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -109.079% |
| International Stem Cell Corporation | 202 Thousand USD | 1255.107% |
| CytoDyn Inc. | -18.02 Million USD | 87.058% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2852.482% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -18980.195% |
| Qrons Inc. | -40.08 Thousand USD | -5721.504% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -380.425% |
| SYBLEU INC | -141.57 Thousand USD | -1548.16% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 542.391% |
| Rebus Holdings, Inc. | -951 Thousand USD | -145.354% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -119.708% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4332.593% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 5.224% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 93.495% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5085.149% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 14.78% |
| Neutra Corp. | -181.24 Thousand USD | -1187.369% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 88.425% |
| PureTech Health plc | -11.62 Million USD | 79.932% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 88.425% |
| IXICO plc | -707 Thousand USD | -230.031% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 69.638% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 95.174% |
| CSL Limited | 4.73 Billion USD | 100.049% |
| Cellectis S.A. | -92.63 Million USD | 97.481% |